Kolon Life Science announced on the 26th that the patent related to the osteoarthritis cell gene therapy 'TG-C' (formerly Invossa), currently being developed by its affiliate Kolon TissueGene, has been registered in Indonesia.
The patent concerns "cartilage regeneration using cartilage cells and TGF-β." It includes technological means to produce transformed cells by introducing TGF-β1 (a gene that inhibits inflammation and promotes the production of cartilage components) into human embryonic kidney-derived GP2-293 cells. It is expected to induce the regeneration of tissue and hyaline cartilage, thus restoring joint function.
The transformed GP2-293 cells had their tumorigenicity completely eliminated through radiation treatment. After expressing TGF-β1 protein for a certain period, they undergo apoptosis. The method of direct injection into the joint cavity has been applied to block systemic exposure and enhance safety.
According to global market research firm Grand View Research, the osteoarthritis treatment market in the Asia-Pacific region is projected to reach $3.35888 billion by 2030. Kim Seon-jin, CEO of Kolon Life Science and Chief Medical Officer of Kolon TissueGene, noted, "We will accelerate our entry into global markets, including Indonesia."